Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company focused on neurodegenerative diseases, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will address the scientific basis for treating Alzheimer's disease as a multi-protein disorder and highlight Annovis' approach of targeting multiple neurotoxic proteins simultaneously through its lead drug candidate, buntanetap, which is currently in a pivotal Phase 3 clinical trial.
The company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
This presentation is significant because it underscores a paradigm shift in Alzheimer's research: moving from targeting single proteins to addressing the multifactorial nature of the disease. Traditional approaches have focused on amyloid beta plaques or tau tangles individually, but clinical outcomes have been limited. Annovis' multi-protein strategy could potentially offer a more comprehensive treatment, addressing the complex pathology that drives disease progression.
The timing is critical as buntanetap is in a pivotal Phase 3 trial. Positive results could position the drug as a first-in-class therapy for Alzheimer's and Parkinson's diseases, which affect millions worldwide. The presentation at Fierce Biotech Week, a prominent industry conference, will provide visibility to the scientific community and investors, potentially influencing research directions and investment flows.
Annovis Bio, headquartered in Malvern, Pennsylvania, is dedicated to developing treatments for neurodegenerative diseases. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.
The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.
